References
- Longo D.L. The use of chemotherapy in the treatment of Hodgkin's,' disease. Semin. Oncol. 1990; 17: 716–735
- Bierman P.J., Armitage O. Role of autotransplantation in Hodgkin's disease. Hematol. Oncol. Clin. North Am. 1993; 7: 591–611
- Anderson J.E., Litzow M.R., Appelbaum F.R., Schoch G., Fisher L.D., Buckner C.D., Petersen F.B., Crawford S.W., Press O.W., Sanders J.E., Bensinger W.I., Martin P.J., Storb R., Sullivan K.M., Hansen J.A., Thomas E.D. Allogenic, syngeneic and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J. Clin. Oncol. 1993; 111: 2342–2350
- Chopra R., McMillan A.K., Linch D.C., Yuklea S., Taghipour G., Pearce R., Patterson K.G., Goldstone A.H. The place of high-dose BEAM therapy and autologous hone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 5: 1137–1145
- Kessinger A., Bierman P.J., Vose J.M., Armitage J.O. High-dose Cyclophosphamide, carmustine and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 77: 2322–2325
- Haas R., Hohaus S., Ehrhardt R., Ogniben E., Boschmann G., Witt B., Hunstein W. Autologous blood stem cell transplantation for patients with Hodgkin's disease in sensitive relapse. Advances in bone marrow purging and processing 1992; 621–627
- Lasky L.C., Huro D.D., Smith J.A., Haake R. Peripheral blood stem cell collection and use in Hodgkin's disease. Tranfusion 1989; 29: 323–327
- Korbling M., Holle R., Haas R., Knouf W., Dorken B., Ho A.D., Kuse R., Pralle R, Flieder T.M., Hunstein W. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J. Clin. Oncol. 1990; 8: 978–985
- Rapoport A.P., Rowe J.M., Kouides P.A., Duerst R.A., Ahhoud C.N., Liesveld J.L., Packman C.H., Eherly S., Sherman M., Tanner M.A., Constine Di L.S., Persio J.F. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J. Clin. Oncol. 1993; 11: 2351–2361
- Sasaki H., Oomochi H., Kawai S., Kikuchi M., Akahane T., Taniguchi N., Sakurai M., Ise T., Taguchi N., Okamura J., Fujimoto T. National survey of 568 cases of malignant childhood lymphoma in Japan. J. Jap. Pediatr. Soc. 1987; 91: 690–700, in Japanese with English abstract
- Makino S., Harada M., Akashi K., Taniguchi S., Shihuya T., Inaha S., Niho Y. A simplified method for cryopreservation of peripheral blood stem cells at -80°C without rate-controlled freezing. Bone Marrow Transplant 1991; 8: 239–244
- Teshima T., Harada M., Takamatsu Y., Makino S., Taniguchi S., Inaba S., Kondo S., Tanaka T., Akashi K., Minamishima I., Ishii E., Nishimura J., Niho Y. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1902; 10: 215–220
- McMillan A., Goldstone A. What is the value of autologous hone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease. Leuk. Res. 1991; 15: 237–243
- Chopra R., Linch D.C., McMillan A.K., Blair S., Patterson K.G., Moir D., Richards J.D.M., Cervi P., Kinsey S., Goldstone A.H. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Brit. J. Haematol. 1992; 81: 197–202
- Linch D.C., Winfield D., Goldstone A.H., Moir D., Hancock B., McMillan A., Chopra R., Milligan D., Vaughan-Hudson G. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993; 341: 1051–1054
- Hiddemann W., Schmits N., Pfreundschuh M., Pflueger K.H., Ollech-Chwoyka J., Tirier C., Maschmeyer G., Kirchner H., Wagner T., Koch P., Dahmen E., Fiedler W., Truemper L., Diehl V. Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Cancer 1990; 66: 838–843
- Brandwein J.M., Callum J., Sutcliffe S.B., Scott J.G., Keating A. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 1990; 5: 99–103
- Broun E.R., Tricot G., Akard L., Nichols C., Cheerva A., Jansen J. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous hone marrow transplantation. Bone Marrow Transplant 1990; 5: 341–344